EP1185635A2 - Non-human transgenic animals deficient in gas6 function and their use - Google Patents
Non-human transgenic animals deficient in gas6 function and their useInfo
- Publication number
- EP1185635A2 EP1185635A2 EP00935193A EP00935193A EP1185635A2 EP 1185635 A2 EP1185635 A2 EP 1185635A2 EP 00935193 A EP00935193 A EP 00935193A EP 00935193 A EP00935193 A EP 00935193A EP 1185635 A2 EP1185635 A2 EP 1185635A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- gas6
- cells
- mice
- endothelial
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002950 deficient Effects 0.000 title claims abstract description 24
- 241001465754 Metazoa Species 0.000 title claims description 17
- 230000009261 transgenic effect Effects 0.000 title claims description 6
- 101150022345 GAS6 gene Proteins 0.000 claims abstract description 105
- 230000004913 activation Effects 0.000 claims abstract description 22
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010048554 Endothelial dysfunction Diseases 0.000 claims abstract description 7
- 230000008694 endothelial dysfunction Effects 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000003511 endothelial effect Effects 0.000 claims description 11
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 38
- 210000002889 endothelial cell Anatomy 0.000 abstract description 28
- 210000000265 leukocyte Anatomy 0.000 abstract description 23
- 239000002158 endotoxin Substances 0.000 abstract description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 13
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 3
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 14
- 210000003038 endothelium Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 206010015866 Extravasation Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036251 extravasation Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010060965 Arterial stenosis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 101100222276 Drosophila melanogaster cuff gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- -1 IL- 1 β Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 101150098329 Tyro3 gene Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000032954 positive regulation of cell adhesion Effects 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000015139 regulation of coagulation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Definitions
- Non-human transqenic animals deficient in Gas6 function and their use.
- the present invention relates to the manufacture of a medicament for the treatment of endothelial dysfunction.
- the present invention further relates to the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of said medicament.
- the endothelium is uniquely positioned at the interface between the blood and the vessel. As such, it performs multiple functions: it is involved in the regulation of coagulation, leukocyte adhesion in inflammation, vessel tone, and vascular smooth muscle cell growth, and also acts as a barrier to transvascular flux of liquids and solutes (Griendling & Alexander, 1996). Far from being a passive participant in these events, it is a dynamic tissue, secreting and modifying vasoactive substances, influencing the behaviour of other cell types, and regulating extracellular matrix production and composition.
- Cardiovascular disorders including atherothrombosis, stroke, arterial (re)-stenosis, ischemic heart disease, myocardial infarction, diabetic macro- and microangiopathy, allograft arteriosclerosis and the like constitute the leading cause of morbidity and mortality in Westernised societies.
- a common feature of all these disorders is activation of the endothelium, which induces interaction with leukocytes (Ross, 1999).
- leukocytes adhere to and infiltrate underneath the endothelium during lipid-induced atherosclerosis (Ross, 1999; Libby et al., 1997; Vadas et al., 1997; Boyle et al., 1997).
- leukocytes During immune-mediated transplant arteriosclerosis or cuff-induced restenosis, leukocytes adhere to the endothelium, subsequently infiltrate in the intima and media, where they activate medial smooth muscle cells to emigrate in the intima, thereby leading to obstructive intimal thickening (Libby et al., 1992).
- leukocytes During ischemia/reperfusion, leukocytes have been involved in the production of toxic substances, leading to tissue destruction (Murohara et al., 1995; Dinerman & Mehta, 1990; DeGraba, 1998; Hallenbeck, 1997; Cavanagh et al., 1998).
- insufficient angiogenesis has been related to impaired responsiveness of the endothelium, such as in the elderly or diabetic patients. Infection and resulting sepsis continue to be important causes of morbidity and mortality, in particular in surgical patients. Emerging evidence implicates the endothelium as a central effector in the inflammatory response (Ahmed & Christou, 1996; McGill et al., 1998; Pajkrt & van Deventer, 1996). Through the expression of surface proteins and secretion of soluble mediators, the endothelium controls vascular tone and permeability, regulates coagulation and thrombosis, and directs the passage of leukocytes into areas of inflammation.
- Metastasis involves adhesion of tumor cells to the endothelium with subsequent extravasation and colonisation in distant tissues. Adhesion of tumor cells is mediated by similar adhesion molecules as used by leukocytes. Endothelial cells in tumors are activated, express more and distinct adhesion molecules, and are often dysfunctional.
- Gas6 Growth arrested gene 6
- fibroblasts increased by serum starvation and contact inhibition, and was therefore implicated in reversible growth arrest (Schneider et al., 1988).
- Gas6 has significant sequence similarity with anticoagulant protein S but lacks anticoagulant activity due to absence of two thrombin cleavage sites. Both molecules are composed of a Gla domain, four EGF-like repeats and a carboxyterminal tandem globular (G)-domains with homology to steroid hormone- binding globulin that are present in molecules involved in cell growth and differentiation (Nakano et al., 1997a).
- Gas6 binds members of the Axl family of receptor tyrosine kinases including Axl (also called Ark, Ufo), Sky (also called Rse, Tyro3, Dtk, Etk, Bit) and Mer (also called Eyk, Nyk) (Crosier and Crosier, 1997; Nagata et al., 1996; Stitt et al., 1995).
- Axl also called Ark, Ufo
- Sky also called Rse, Tyro3, Dtk, Etk, Bit
- Mer also called Eyk, Nyk
- the extracellular domain of these receptors posses Ig-like motifs and fibronectin type III modules, found in cell adhesion molecules.
- a truncated soluble Axl form is proteolytically generated but it remains unknown whether this soluble receptor acts as a competitive inhibitor for Gas6 by sequestering free ligand, is involved in binding Axl directly and originating a signal distinct from Gas6, or in inactivating the receptor on the cell surface (Costa et al., 1996).
- Gas6 is expressed in lung and intestine (Manfioletti et al., 1993).
- Sky is predominantly expressed in the brain
- Mer is expressed in monocytes (from peripheral blood and bone marrow) and in cells derived from epithelial tissues (lung, kidney) and reproductive tissues (ovary, prostate), but not in unstimulated granulocytes.
- Axl is also expressed in monocytes but not in unstimulated granulocytes or mature B or T lymphocytes.
- Gas6 and Axl are expressed by vascular endothelial cells (Manfioletti et al., 1993).
- Gas6 The function of Gas6 remains largely undetermined and controversial. Gas ⁇ has been reported to inhibit homophiiic Axl-mediated aggregation of myeloid cells (Avanzi et al., 1998), but cell-bound Gas6 may mediate aggregation of myeloid cells via interaction with Axl receptor on adjacent cells (McCloskey et al., 1997). Gas6 did not affect adhesion of granulocytes to resting endothelial cells, while it inhibited granulocyte adhesion to TNF-alpha activated endothelial cells, but only at high concentrations (Avanzi et al., 1998).
- Gas6 is mitogenic for fibroblasts (Goruppi et al., 1996) and Schwann cells (Li et al., 1996) but not for myeloid cells (Avanzi et al., 1997) or endothelial cells (Avanzi et al., 1998).
- Gas6 also acts as a survival factor for serum-starved fibroblasts (Goruppi et al., 1996) and GnRH neuronal cells (Allen et al., 1999), presumably via activation of PI3-kinase and Akt kinase (Goruppi et al., 1997).
- Ark signalling protects against apoptosis induced by serum withdrawal or TNF-alpha, but the increased apoptosis of Ark deficient fibroblasts after serum- withdrawal could not be rescued by Gas6 (Bellosta et al., 1997).
- Gas6 may play a role in clearance of apoptotic cells by forming a bridge between phosphatidylserine on the surface of apoptotic cells and Axl on phagocytotic cells (Nakano et al., 1997b).
- endothelial cells exhibit a unique plasticity to rapidly proliferate and migrate, or to become activated to express prothrombotic factors or leukocyte adhesion molecules.
- Such responsiveness is essential to accommodate rapidly changing needs to vascularize ischemic tissues, to provide hemostasis upon vascular trauma, to mediate leukocyte extravasation in inflamed tissues or to provide adequate vasomotor control during abnormal tissue perfusion.
- the molecular mechanisms that allow quiescent endothelial cells to exhibit such rapid responsiveness remain undetermined.
- the present invention concerns an animal deficient in Gas6 function.
- said animal is a transgenic animal in which the Gas6 alleles are inactivated (Gas6 'A ). More preferably, said animal is a Gas6 " ⁇ mouse.
- the invention relates to the use of said Gas6 deficient animal to study the role of Gas6.
- Said Gas6 deficient transgenic animals can be used for screening compounds having an effect, positive or negative, on said endothelial dysfunction.
- the invention provides a method to screen for inhibitors of Gas6 function and/or inhibitors of a Gas6 receptor that result in an inhibition of the endothelial activation.
- inhibitors of Gas6 function are soluble forms of the Gas6 receptor and/or Gas6 neutralising antibodies.
- Gas6 inhibitors may be compounds that prevent the binding of Gas6 to its receptor and/or the activation of said receptor.
- the invention provides the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of a medicament to treat endothelial dysfunction.
- Activation of Gas6 receptor depends on the type of receptor and is known to the people skilled in the art.
- Gas6 tyrosine kinase type receptors it has been extensively described in W09628548 and refers to the step of causing the intracellular domain of the receptor to phosphorylate tyrosine residues in a substrate polypeptide.
- Inhibitor of Gas6 receptor any compound that prevents the activation of said receptor.
- Gas6 neutralising antibody any antibody that prevents Gas6 to execute its function.
- Inhibitor of Gas6 function any compound that prevents Gas6 to execute its function. This inhibition may be due to actions such as chemical modification, denaturation of the tertiary structure, complex formation or proteolysis.
- Gas6 function binding of Gas6 with a Gas6 receptor. Bind(ing) means any kind of interaction, be it direct (direct interaction of Gas6 with the extracellular domain of said receptor) or indirect (interaction of Gas6 with one or more identical and/or non- identical compounds resulting in a complex of which one or more compounds can interact with the extracellular domain) that results in activation of the Gas6 receptor.
- the extracellular domain means the domain as it occurs in the natural Gas6 receptors, or a fragment thereof, eventually fused to other amino acid sequences, characterised in that it is still able to bind Gas6.
- Compound any chemical or biological compound, including simple inorganic or organic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.
- Example 1 inhibition of endothelial activation by Gas6 gene-inactivation in mice
- the Gas6 gene was inactivated in embryonic stem cells via homologous recombination, and Gas6 deficient mice were generated. Surprisingly, these knockout mice developed normally, survived, and were apparently healthy. However, when the Gas6 deficient mice were challenged with inflammatory stimuli, they were found to be protected against endothelial activation.
- mice Eight to twelve week old WT and Gas6 " ⁇ mice of either sex with a genetic background of 75% C57BI6 and 25%129/Sv, and weighing 20-30 g, were used. Animals were maintained in an open animal facility and experiments were performed according to the guidelines of the institutional animal care committee. Adult mice were intraperitoneally injected with endotoxin (0, 10 and 20 mg/kg) and after 12 h, mice were anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital. Blood was collected in citrate via vena cava puncture with a 24-gauge needle. Following centrifugation at 3000 rpm for 10 min, plasma was collected and stored at -20° C until analysis.
- Factor VII activity was measured via the Coatest FVII assay, as described by the manufacturer (Chromogenix, Brussels, Belgium).
- the coagulant activity of the other factors was determined as a clotting time after mixing the murine plasma with human plasma, deficient in the specific factor and addition of thromboplastin (for Fll, FV, FVII, FX) or kaolin (FIX) in the University Hospital (UZ Gasthuisberg, Leuven, Belgium). All procoagulant activities were expressed as a percent of the procoagulant activity in a plasma pool of adult wild type mice.
- Plasma fibrinogen was determined by a coagulation rate assay (Vermylen et al., 1963).
- mice In order to obtain mouse capillary endothelial cells, anaesthetized mice were injected s.c. with 500 ⁇ l of ice-cold matrigel containing VEGF (100 ng/ml) and heparin (300 ⁇ g/ml). After 7 days, the pellet containing neovessels was dissected and enzymatically dispersed using 0.1% type II collagenase (Sigma, St Louis, Mo). Mouse endothelial cells were routinely cultured in T75 flasks coated with 0.1% gelatin in M131 medium supplemented with 5% MVGS (ref S005025; Gibco-BRL). For passage, cells were detached by trypsin/EDTA (0.02-0.05%).
- VEGF 100 ng/ml
- heparin 300 ⁇ g/ml
- TNF- ⁇ stimulation endothelial cells were refed with fresh culture medium containing 100 ng/ml TNF- ⁇ (R&D, Abingdon, UK). After 24 hr, the conditioned medium was harvested and analyzed for the following cytokines: IL-1 ⁇ and IL-6 (QuantikineTM M, R&D, Abindon, UK); ELAM, ICAM, VCAM and tissue factor (all from R&D).
- mice were intraperitoneally injected with endotoxin (20 mg/kg) and after 90 or 180 min, the mice were anesthetized by intraperitoneal injection of 60 mg kg sodium pentobarbital. Blood was collected in citrate by vena cava puncture with a 24-gauge needle. Following centrifugation at 3000 rpm for 10 min, plasma was collected and stored at -20° C until analysis. Cytokines were measured using QuantikineTM M assays for IL-1 ⁇ , IL-6, IL-10 and TNF- ⁇ according to the manufacturer's instructions (all from R&D, Abindon, UK).
- mouse endothelial cells were cultured in T75 flasks coated with 0.1 % gelatine in RPMI 1640 medium containing 10% foetal calf serum (Life Technologies, Paisley, UK), 100 IU penicillin, 100 ⁇ g/ml streptomycin, 2 mM glutamine, heparin (100 ⁇ g/ml) and endothelial cell growth supplement (30 ⁇ g/ml).
- Apoptosis was induced by (i) supplementation of TNF- ⁇ (100 ng/ml; R&D), Fas- ligand (100 ng/ml; R&D), or withdrawal from growth factors (0.1 % foetal calf serum).
- Apoptosis was quantified by measuring cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) using a photometric enzyme immunoassay (Cell Detection ELISA, Boehringer Mannheim, Mannheim, Germany).
- tissue factor the initiator of blood coagulation
- a mouse model of arterial stenosis based on ligation is used. Previous studies have indicated that following ligation, the endothelium becomes activated, resulting in adhesion of leukocytes to the endothelium, with subsequent infiltration in the intima and media (Kockx et a/., 1993). Due to leukocyte production of growth factors and cytokines, medial smooth muscle cells become activated, proliferate and migrate backwards into the intima, thereby forming a neointima, rich in smooth muscle cells. Wild type and Gas6 " ⁇ mice were subjected to ligation of the right common carotid artery, just proximal to the bifurcation, with silk 4/0.
- Ischemic brain injury was achieved by permanently ligating and sectioning the middle cerebral artery. Infarct size was morphometrically measured after TTC staining of 1 mm thick brain slices within 24 hrs after ligation as described by Nagai et al. (1999). Ischemic brain injury was significantly reduced in Gas6 ' ⁇ as compared to Gas6 + mice after ligation of the middle cerebral artery (Table 6).
- Example 4 in vivo role of Gas6 in angiogenesis
- endothelial cells in the adult are quiescent, and need to become activated when new blood vessels are formed.
- Angiogenesis inhibitors have attained significant interest for the treatment of cancer, inflammatory disorders and diabetic retinopathy, as endothelial cells that invade tumors are non-tumoral host-derived cells, that would not become resistant to chemotherapy (Folkman, 1998).
- Ingrowth of capillaries in matrigel was performed as described by Passanti et al. (1992). Briefly, 500 ⁇ l ice-cold matrigel containing heparin (300 ⁇ g/ml) and rVEGFies (100ng/ml) was injected subcutaneaously into the groin. After 7 days, the matrigel pellet with the neovessels was dissected for analysis of neovascularisation: one part was homogenized to determine the hemoglobin content determined using Drabkin's reagent (Sigma, St. Quentin Fallavier, France), whereas the other part was fixed in 1 % paraformaldehyde for histological analysis.
- Drabkin's reagent Sigma, St. Quentin Fallavier, France
- Avanzi, G.C. et al. GAS6 inhibits granulocyte adhesion to endothelial cells.
- Thromb Haemost 78, 60-64 (1997).
- Golino, P. et al. Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury.
- Thromb Haemost 77, 783-788 (1997).
- Table 1 Coagulation and hematological parameters after endotoxin injection (20 mg/kg).
- mice mice
- mice Plasma concentrations of coagulation factors (expresses in % of normal pool), platelets and leukocytes in mice within 12 h after injection of endotoxin (0-10 and 20 mg/kg).
- Table 2 Serum cytokine concentration after endotoxin injection (20 mg/kg).
- mice Data represent mean ⁇ SD (7 mice) of cytokine serum concentrations in mice after injection of endotoxin (20 mg/kg).
- Data represent mean ⁇ SD (9) of cytokine concentrations (ng/10 cells).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
It has been shown that Gas6 deficient endothelial cells are resistant to activation by endotoxin and TNF-α in vitro and in vivo and that leukocytes did not or much less extravasate in Gas6 deficient mice. The present invention also relates to the manufacture of a medicament for the treatment of endothelial dysfunction. The present invention further relates to the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of said medicament.
Description
Non-human transqenic animals deficient in Gas6 function and their use.
The present invention relates to the manufacture of a medicament for the treatment of endothelial dysfunction. The present invention further relates to the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of said medicament.
The endothelium is uniquely positioned at the interface between the blood and the vessel. As such, it performs multiple functions: it is involved in the regulation of coagulation, leukocyte adhesion in inflammation, vessel tone, and vascular smooth muscle cell growth, and also acts as a barrier to transvascular flux of liquids and solutes (Griendling & Alexander, 1996). Far from being a passive participant in these events, it is a dynamic tissue, secreting and modifying vasoactive substances, influencing the behaviour of other cell types, and regulating extracellular matrix production and composition. One of the most important events in the reaction to all forms of injury is adhesion of leukocytes to activated endothelium, a prelude to their emigration into tissues (Cotran & Mayadas-Norton, 1998). Not surprisingly, therefore, when endothelial cells become dysfunctional or deregulated, they may contribute significantly to the development of numerous disorders with major morbidity and mortality, some of which are listed hereunder.
Cardiovascular disorders including atherothrombosis, stroke, arterial (re)-stenosis, ischemic heart disease, myocardial infarction, diabetic macro- and microangiopathy, allograft arteriosclerosis and the like constitute the leading cause of morbidity and mortality in Westernised societies. A common feature of all these disorders is activation of the endothelium, which induces interaction with leukocytes (Ross, 1999). For example, leukocytes adhere to and infiltrate underneath the endothelium during lipid-induced atherosclerosis (Ross, 1999; Libby et al., 1997; Vadas et al., 1997; Boyle et al., 1997). During immune-mediated transplant arteriosclerosis or cuff-induced restenosis, leukocytes adhere to the endothelium, subsequently infiltrate in the intima and media, where they activate medial smooth muscle cells to emigrate in the intima, thereby leading to obstructive intimal thickening (Libby et al., 1992). During ischemia/reperfusion, leukocytes have been involved in the
production of toxic substances, leading to tissue destruction (Murohara et al., 1995; Dinerman & Mehta, 1990; DeGraba, 1998; Hallenbeck, 1997; Cavanagh et al., 1998).
Excessive formation of new blood vessels (neovascularisation) promotes progression of cancers, induces diabetic retinopathy leading to blindness, and contributes to chronic inflammatory disorders (rheumatoid arthritis, non-healing ulcerations) (Folkman, 1995). In order for endothelial cells to form new blood vessels, they first need to become activated by angiogenic molecules (Carmeliet & Collen, 1998). Leukocytes and tumor cells, adhering to the endothelium, play an essential role in the induction of pathological neovascularization by production of angiogenic factors (Schaper & Ito, 1996). The morbidity and mortality associated with abnormal angiogenesis is significant. Conversely, insufficient angiogenesis has been related to impaired responsiveness of the endothelium, such as in the elderly or diabetic patients. Infection and resulting sepsis continue to be important causes of morbidity and mortality, in particular in surgical patients. Emerging evidence implicates the endothelium as a central effector in the inflammatory response (Ahmed & Christou, 1996; McGill et al., 1998; Pajkrt & van Deventer, 1996). Through the expression of surface proteins and secretion of soluble mediators, the endothelium controls vascular tone and permeability, regulates coagulation and thrombosis, and directs the passage of leukocytes into areas of inflammation. Derangements in these normal functions may contribute significantly to a maladaptive inflammatory response leading to systemic inflammation, multiple organ failure, and "diffuse intravascular coagulation", a life-threatening complication. Metastasis involves adhesion of tumor cells to the endothelium with subsequent extravasation and colonisation in distant tissues. Adhesion of tumor cells is mediated by similar adhesion molecules as used by leukocytes. Endothelial cells in tumors are activated, express more and distinct adhesion molecules, and are often dysfunctional. Collectively, a better understanding of the molecular basis leading to activation of endothelial cells is mandated in order to design more rationally future treatments for these life-threatening and debilitating disorders. Considering its enormous surface area (equivalent in adults to an entire soccer field) and accessibility, it is not
surprising that this "organ" plays an important role in the above-mentioned disorders. The identification of candidates involved in this process may constitute attractive targets for development of drugs for treatment of such disorders. Previous studies using inhibitors or in gene-inactivated mice have amply demonstrated the importance of endothelial activation and endothelial-leukocyte interaction in cardiovascular disorders (Frenette & Wagner, 1997).
Growth arrested gene 6 (Gas6) was originally identified as a gene, whose expression in fibroblasts increased by serum starvation and contact inhibition, and was therefore implicated in reversible growth arrest (Schneider et al., 1988). Gas6 has significant sequence similarity with anticoagulant protein S but lacks anticoagulant activity due to absence of two thrombin cleavage sites. Both molecules are composed of a Gla domain, four EGF-like repeats and a carboxyterminal tandem globular (G)-domains with homology to steroid hormone- binding globulin that are present in molecules involved in cell growth and differentiation (Nakano et al., 1997a).
Gas6 binds members of the Axl family of receptor tyrosine kinases including Axl (also called Ark, Ufo), Sky (also called Rse, Tyro3, Dtk, Etk, Bit) and Mer (also called Eyk, Nyk) (Crosier and Crosier, 1997; Nagata et al., 1996; Stitt et al., 1995). The extracellular domain of these receptors posses Ig-like motifs and fibronectin type III modules, found in cell adhesion molecules. A truncated soluble Axl form is proteolytically generated but it remains unknown whether this soluble receptor acts as a competitive inhibitor for Gas6 by sequestering free ligand, is involved in binding Axl directly and originating a signal distinct from Gas6, or in inactivating the receptor on the cell surface (Costa et al., 1996). Gas6 is expressed in lung and intestine (Manfioletti et al., 1993). Sky is predominantly expressed in the brain, while Mer is expressed in monocytes (from peripheral blood and bone marrow) and in cells derived from epithelial tissues (lung, kidney) and reproductive tissues (ovary, prostate), but not in unstimulated granulocytes. Axl is also expressed in monocytes but not in unstimulated granulocytes or mature B or T lymphocytes. Gas6 and Axl are expressed by vascular endothelial cells (Manfioletti et al., 1993).
The function of Gas6 remains largely undetermined and controversial. Gasδ has been reported to inhibit homophiiic Axl-mediated aggregation of myeloid cells
(Avanzi et al., 1998), but cell-bound Gas6 may mediate aggregation of myeloid cells via interaction with Axl receptor on adjacent cells (McCloskey et al., 1997). Gas6 did not affect adhesion of granulocytes to resting endothelial cells, while it inhibited granulocyte adhesion to TNF-alpha activated endothelial cells, but only at high concentrations (Avanzi et al., 1998). Gas6 is mitogenic for fibroblasts (Goruppi et al., 1996) and Schwann cells (Li et al., 1996) but not for myeloid cells (Avanzi et al., 1997) or endothelial cells (Avanzi et al., 1998). Gas6, induced in injured vascular smooth muscle cells, induces Axl-mediated chemotaxis of smooth muscle cells (Fridell et al., 1998) and, although not mitogenic by itself, enhances the mitogenic activity of thrombin (Fridell et al., 1998). Gas6 also acts as a survival factor for serum-starved fibroblasts (Goruppi et al., 1996) and GnRH neuronal cells (Allen et al., 1999), presumably via activation of PI3-kinase and Akt kinase (Goruppi et al., 1997). Ark signalling protects against apoptosis induced by serum withdrawal or TNF-alpha, but the increased apoptosis of Ark deficient fibroblasts after serum- withdrawal could not be rescued by Gas6 (Bellosta et al., 1997). Gas6 may play a role in clearance of apoptotic cells by forming a bridge between phosphatidylserine on the surface of apoptotic cells and Axl on phagocytotic cells (Nakano et al., 1997b).
Since growth-arrested genes are characteristically expressed when cells undergo growth arrest, the role of Gas6 in endothelial biology was examined. Indeed, endothelial cells become quiescent and enter a state of prolonged growth arrest
(half-life estimated to be ~ 30 years in humans), once vascular development during embryogenesis and postnatal growth is accomplished, and abundantly express
Gas6. However, in contrast to other growth-arrested cells (including terminally differentiated cardiomyocytes or neurons), endothelial cells exhibit a unique plasticity to rapidly proliferate and migrate, or to become activated to express prothrombotic factors or leukocyte adhesion molecules. Such responsiveness is essential to accommodate rapidly changing needs to vascularize ischemic tissues, to provide hemostasis upon vascular trauma, to mediate leukocyte extravasation in inflamed tissues or to provide adequate vasomotor control during abnormal tissue perfusion. Notably, the molecular mechanisms that allow quiescent endothelial cells to exhibit such rapid responsiveness remain undetermined.
Collectively, despite the above-mentioned data, the precise role of Gas6 and its receptors, in particular in endothelial (patho)-biology in vivo, remains largely undetermined.
In this invention it has been surprisingly found that Gas6 deficient endothelial cells are resistant to activation by endotoxin and TNF-α in vitro and in vivo and that leukocytes did not or much less extravasate in Gas6 deficient mice. This proves that Gas6 plays an essential role in the activation of the endothelium in response to inflammatory stimuli. Since numerous cardiovascular, cancerous and infectious disorders, as indicated above, implicate endothelial activation with subsequent binding and extravasation of leukocytes, Gas6 antagonists and Gas6 receptor inhibitors can be used as compounds for the manufacture of a medicament for the treatment of said disorders.
In a first aspect the present invention concerns an animal deficient in Gas6 function. Preferably, said animal is a transgenic animal in which the Gas6 alleles are inactivated (Gas6'A). More preferably, said animal is a Gas6"Λ mouse.
In another aspect the invention relates to the use of said Gas6 deficient animal to study the role of Gas6. Said Gas6 deficient transgenic animals can be used for screening compounds having an effect, positive or negative, on said endothelial dysfunction. In another aspect the invention provides a method to screen for inhibitors of Gas6 function and/or inhibitors of a Gas6 receptor that result in an inhibition of the endothelial activation. Preferably, inhibitors of Gas6 function are soluble forms of the Gas6 receptor and/or Gas6 neutralising antibodies. Alternatively, Gas6 inhibitors may be compounds that prevent the binding of Gas6 to its receptor and/or the activation of said receptor.
In still another aspect, the invention provides the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of a medicament to treat endothelial dysfunction.
Definitions
The following definitions are set forth to illustrate the meaning and scope of the various terms used to describe the invention therein.
Activation of Gas6 receptor: depends on the type of receptor and is known to the people skilled in the art. For Gas6 tyrosine kinase type receptors, it has been extensively described in W09628548 and refers to the step of causing the intracellular domain of the receptor to phosphorylate tyrosine residues in a substrate polypeptide. Inhibitor of Gas6 receptor: any compound that prevents the activation of said receptor.
Gas6 neutralising antibody: any antibody that prevents Gas6 to execute its function. Inhibitor of Gas6 function: any compound that prevents Gas6 to execute its function. This inhibition may be due to actions such as chemical modification, denaturation of the tertiary structure, complex formation or proteolysis.
Gas6 function: binding of Gas6 with a Gas6 receptor. Bind(ing) means any kind of interaction, be it direct (direct interaction of Gas6 with the extracellular domain of said receptor) or indirect (interaction of Gas6 with one or more identical and/or non- identical compounds resulting in a complex of which one or more compounds can interact with the extracellular domain) that results in activation of the Gas6 receptor. The extracellular domain means the domain as it occurs in the natural Gas6 receptors, or a fragment thereof, eventually fused to other amino acid sequences, characterised in that it is still able to bind Gas6. Compound: any chemical or biological compound, including simple inorganic or organic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.
Examples
Example 1: inhibition of endothelial activation by Gas6 gene-inactivation in mice In order to study the role of Gas6 in vivo, the Gas6 gene was inactivated in embryonic stem cells via homologous recombination, and Gas6 deficient mice were generated. Surprisingly, these knockout mice developed normally, survived, and were apparently healthy. However, when the Gas6 deficient mice were challenged with inflammatory stimuli, they were found to be protected against endothelial activation.
Eight to twelve week old WT and Gas6"Λ mice of either sex with a genetic background of 75% C57BI6 and 25%129/Sv, and weighing 20-30 g, were used. Animals were maintained in an open animal facility and experiments were performed according to the guidelines of the institutional animal care committee. Adult mice were intraperitoneally injected with endotoxin (0, 10 and 20 mg/kg) and after 12 h, mice were anesthetized by intraperitoneal injection of 60 mg/kg sodium pentobarbital. Blood was collected in citrate via vena cava puncture with a 24-gauge needle. Following centrifugation at 3000 rpm for 10 min, plasma was collected and stored at -20° C until analysis. Factor VII activity was measured via the Coatest FVII assay, as described by the manufacturer (Chromogenix, Brussels, Belgium). The coagulant activity of the other factors was determined as a clotting time after mixing the murine plasma with human plasma, deficient in the specific factor and addition of thromboplastin (for Fll, FV, FVII, FX) or kaolin (FIX) in the University Hospital (UZ Gasthuisberg, Leuven, Belgium). All procoagulant activities were expressed as a percent of the procoagulant activity in a plasma pool of adult wild type mice. Plasma fibrinogen was determined by a coagulation rate assay (Vermylen et al., 1963). For hematological analysis, blood was collected in 0.01 volume 4% trisodium citrate, and cells were counted using an automated analyzer (Cell-Dyn 610U-Hematology Analyzer; Sequioa-Turner Co, Mountain View, CA). Cell counts are expressed per millilitres of whole blood.
In order to obtain mouse capillary endothelial cells, anaesthetized mice were injected s.c. with 500 μl of ice-cold matrigel containing VEGF (100 ng/ml) and heparin (300 μg/ml). After 7 days, the pellet containing neovessels was dissected and enzymatically dispersed using 0.1% type II collagenase (Sigma, St Louis, Mo).
Mouse endothelial cells were routinely cultured in T75 flasks coated with 0.1% gelatin in M131 medium supplemented with 5% MVGS (ref S005025; Gibco-BRL). For passage, cells were detached by trypsin/EDTA (0.02-0.05%). For TNF-α stimulation, endothelial cells were refed with fresh culture medium containing 100 ng/ml TNF-α (R&D, Abingdon, UK). After 24 hr, the conditioned medium was harvested and analyzed for the following cytokines: IL-1 β and IL-6 (Quantikine™ M, R&D, Abindon, UK); ELAM, ICAM, VCAM and tissue factor (all from R&D). Recombinant Gas6, produced in 293 monkey kidney cells stably transfected with the pcDNA3 expressing vector encoding the mouse Gas6 cDNA (Grinnell et al., 1990), was supplemented at 200 ng/ml during the experiment as indicated.
For the determination of cytokine concentration after endotoxin injection, adult mice were intraperitoneally injected with endotoxin (20 mg/kg) and after 90 or 180 min, the mice were anesthetized by intraperitoneal injection of 60 mg kg sodium pentobarbital. Blood was collected in citrate by vena cava puncture with a 24-gauge needle. Following centrifugation at 3000 rpm for 10 min, plasma was collected and stored at -20° C until analysis. Cytokines were measured using Quantikine™ M assays for IL-1 β, IL-6, IL-10 and TNF-α according to the manufacturer's instructions (all from R&D, Abindon, UK). For apoptosis studies, mouse endothelial cells were cultured in T75 flasks coated with 0.1 % gelatine in RPMI 1640 medium containing 10% foetal calf serum (Life Technologies, Paisley, UK), 100 IU penicillin, 100 μg/ml streptomycin, 2 mM glutamine, heparin (100 μg/ml) and endothelial cell growth supplement (30 μg/ml). Apoptosis was induced by (i) supplementation of TNF-α (100 ng/ml; R&D), Fas- ligand (100 ng/ml; R&D), or withdrawal from growth factors (0.1 % foetal calf serum). Apoptosis was quantified by measuring cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) using a photometric enzyme immunoassay (Cell Detection ELISA, Boehringer Mannheim, Mannheim, Germany).
Protection against endothelial activation was concluded based on the following criteria:
- Intravenous injection of endotoxin in wild type mice induced strong activation of the coagulation cascade, resulting in reduced levels of factor II, factor V, factor VIII, factor X, and fibrinogen (Table 1). In addition, platelet counts were reduced after
endotoxin, indicating formation of platelet-rich thrombi (Table 1 ). In contrast, endotoxin completely failed to activate coagulation and consume platelets in Gas6 deficient mice (Table 1 ), despite comparable increase in plasma levels of IL-6, IL- 1 β, IL-10 and TNF-α (Table 2). Upon local injection of endotoxin (50μg) in the footpad, significantly fewer veins developed occluding thrombosis in Gas6v" than in Gasδ47"1" mice (Table 3).
When cultured endothelial cells from wild type mice were treated with TNF-α, they expressed increased levels of tissue factor (the initiator of blood coagulation) (Table 4). In contrast, tissue factor could not be induced by TNF-α in Gas6 deficient endothelial cells.
- Intravenous injection of endotoxin (10 to 40 mg/kg) in wild type mice reduced circulating numbers of leukocytes, which extravasated in peripheral tissues such as the lung, kidney and heart (Table 1 ). In contrast, leukocyte numbers in the peripheral blood remained high in Gas6 deficient mice, and leukocytes failed to extravasate. In contrast to cultured wild type endothelial cells, Gas6 deficient endothelial cells failed to express upregulated levels of VCAM, ICAM, and ELAM in response to TNF-α. Further, secretion of IL-1 β and IL-6 was abrogated in Gas6 deficient cells (Table 4). Upon local injection of endotoxin (50 μg) in the footpad significantly fewer leukocytes adhered to the arterial endothelial cells in Gasδ" " than in Gas6+/+ mice (Table 3)
- Anti-Fas antibodies induced severe apoptotic liver damage leading to fulminant hepatitits, liver haemorrhage, and death in wild type mice, whereas Gas6 deficient mice were almost completely protected (number of TUNEL positive cells per optical field: 28 ± 7 for Gas6+/+ versus 8 ± 1 for Gase7"). Gas6 deficient endothelial cells, unlike wild type cells, are also protected against apoptosis, induced by a cocktail of cytokines (Table 5). Upon local injection of endotoxin (50 μg) in the footpad, significantly fewer apoptotic (TUNEL-positive) endothelial cells were present in Gas6" '' than in Gas6+ + mice (Table 3) Collectively, these data unveil a novel role for Gasδ. Gas6 plays a role in activation of endothelial cells and subsequent binding and extravasation of leukocytes in response to various inflammatory or noxious stimuli. These data illustrate the role of Gas6 in mediating adhesion between activated endothelial and leukocytes.
Example 2: in vivo role of Gas6 in arterial stenosis
A mouse model of arterial stenosis based on ligation is used. Previous studies have indicated that following ligation, the endothelium becomes activated, resulting in adhesion of leukocytes to the endothelium, with subsequent infiltration in the intima and media (Kockx et a/., 1993). Due to leukocyte production of growth factors and cytokines, medial smooth muscle cells become activated, proliferate and migrate backwards into the intima, thereby forming a neointima, rich in smooth muscle cells. Wild type and Gas6"Λ mice were subjected to ligation of the right common carotid artery, just proximal to the bifurcation, with silk 4/0. Two weeks after ligation, the luminal stenosis, expressed in percent of the area within the internal elastic lamina was 37 ± 5.8% in wild type and 18 ± 3.5% in Gas6"Λ mice (mean ± SEM, n= 8, p= 0.012).
From the results, it is clear that Gas6 deficient mice develop less arterial intimal thickening.
Example 3: in vivo role of Gas6 in stroke
A growing body of evidence indicates that inflammatory mechanisms contribute to secondary neuronal injury after acute cerebral ischemia (DeGabra, 1998; Hallenbeck, 1997). Ischemia followed by reperfusion rapidly leads to the expression of inflammatory cytokines, particularly TNF-α and I L- 1 β , which stimulate a complex cascade of events involving endothelial cells, neurons, astrocytes, and perivascular cells. A secondary response involves activation of the coagulation system and upregulation of cell adhesion molecules. The net effect of these events is transformation of the local endothelium to a prothrombotic/proinfiammatory state and induction of leukocyte migration to the site of injury within hours of reperfusion. Leukocytes cause tissue injury by several mechanisms, including occlusion of microvasculature, generation of oxygen free radicals, release of cytotoxic enzymes, alteration of vasomotor reactivity, and increase in cytokine and chemoattractant release. A mouse model of stroke, based on ligation of the middle cerebral artery, was developed to study the role of plasminogen system proteinases in vivo (Nagai et al., 1999) and was used to the study the role of Gas6. Ischemic brain injury was achieved by permanently ligating and sectioning the middle cerebral artery. Infarct size was morphometrically measured after TTC staining of 1 mm thick brain slices
within 24 hrs after ligation as described by Nagai et al. (1999). Ischemic brain injury was significantly reduced in Gas6'Λ as compared to Gas6 + mice after ligation of the middle cerebral artery (Table 6).
Example 4: in vivo role of Gas6 in angiogenesis
Unlike their active growth and remodeling during embryonic development, endothelial cells in the adult are quiescent, and need to become activated when new blood vessels are formed. Over the last decade, remarkable progress has been made in the identification of a variety of molecules that stimulate or inhibit angiogenesis in vivo. Angiogenesis inhibitors have attained significant interest for the treatment of cancer, inflammatory disorders and diabetic retinopathy, as endothelial cells that invade tumors are non-tumoral host-derived cells, that would not become resistant to chemotherapy (Folkman, 1998).
Ingrowth of capillaries in matrigel was performed as described by Passanti et al. (1992). Briefly, 500 μl ice-cold matrigel containing heparin (300 μg/ml) and rVEGFies (100ng/ml) was injected subcutaneaously into the groin. After 7 days, the matrigel pellet with the neovessels was dissected for analysis of neovascularisation: one part was homogenized to determine the hemoglobin content determined using Drabkin's reagent (Sigma, St. Quentin Fallavier, France), whereas the other part was fixed in 1 % paraformaldehyde for histological analysis. Subcutaneous injection of matrigel containing VEGF induced a strong angiogenic ingrowth of capillaries in wild type mice, while this angiogenic response was inhibited for more than 80% in Gas6 deficient mice (Table 7). The significant suppression of angiogenesis in Gas6 deficient mice suggests that Gas6, somehow, is required for endothelial activation during angiogenesis, and that Gas6 antagonists may be useful angiogenesis inhibitors.
References
Ahmed, N. & Christou, N. Systemic inflammatory response syndrome: interactions between immune cells and the endothelium. Shock 6, S39-42 (1996). Allen, M.P. et al. Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt [In Process Citation]. Mol Endocrinol 13, 191 -201 (1999). Avanzi, G.C. et al. GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. Exp Hematol 25, 1219-1226 (1997).
Avanzi, G.C. et al. GAS6 inhibits granulocyte adhesion to endothelial cells. Blood
91 , 2334-2340 (1998). Bajou, K. et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med *, 923-928 (1998). Beliosta, P., Costa, M., Lin, D.A. & Basilico, C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15, 614-625 (1995). Beliosta, P., Zhang, Q., Goff, S.P. & Basilico, C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15, 2387-2397 (1997).
Boyle, E.M., Jr., Lille, ST., Allaire, E., Clowes, A.W. & Verrier, E.D. Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg 63, 885-894 (1997). Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin
Invest 99, 200-208 (1997a). Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice [see comments]. Circulation 96, 3180-3191 (1997b). Carmeliet, P. et al. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ Res 81 , 829-839 (1997c).
Carmeliet, P. et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17, 439-444
(1997d). Carmeliet, P., Stassen, J.M., Meidell, R., Collen, D. & Gerard, R. Adenovirus- mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice.
Blood 90, 1527-1534 (1997e) Carmeliet, P. & Collen, D. Vascular development and disorders: molecular analysis and pathogenetic insights. Kidney Int 53, 1519-1549 (1998). Carmeliet, P. et al. Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J Cell Biol 140,
233-245 (1998a). Carmeliet, P. et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 394, 485-490 (1998b). Cavanagh, S.P., Gough, M.J. & Homer-Vanniasinkam, S. The role of the neutrophil in ischaemia-reperfusion injury: potential therapeutic interventions. Cardiovasc
Surg β, 112-118 (1998). Cosentino, F. & Luscher, T.F. Endothelial dysfunction in diabetes mellitus [In
Process Citation]. J Cardiovasc Pharmacol 32, S54-61 (1998). Costa, M., Beliosta, P. & Basilico, C. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. J Cell Physiol 168, 737-744
(1996). Cotran, R.S. & Mayadas-Norton, T. Endothelial adhesion molecules in health and disease. Pathol Biol (Paris) 46, 164-170 (1998). Couffinhal, T. et al. Mouse model of angiogenesis. Am J Pathol 152, 1667-1679 (1998).
Crosier, K.E. & Crosier, P.S. New insights into the control of cell growth; the role of the Axl family. Pathology 29, 131-135 (1997). DeGraba, T.J. The role of inflammation after acute stroke: utility of pursuing anti- adhesion molecule therapy. Neurology 5Λ , S62-68 (1998). Dinerman, J.L. & Mehta, J.L. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance [see comments]. J Am Coll Cardiol 16, 207-222 (1990).
Dong, Z.M. & Wagner, D.D. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 132, 369-375 (1998). Fernandes, P. B. (1998). Technological advances in high-throughput screening.
Curr Opin Chem Biol 2, 597-603 Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease.
Nature Med 1 , 27-31 (1995). Folkman, J. Antiangiogenic gene therapy. Proc Nat! Acad Sci U S A 95, 9064-9066
(1998). Fridell, Y.W., Villa, J., Jr., Attar, E.C. & Liu, E.T. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 273, 7123-7126
(1998). Frenette, P.S. & Wagner, D.D. Insights into selectin function from knockout mice.
Thromb Haemost 78, 60-64 (1997). Golino, P. et al. Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 77, 783-788 (1997).
Goruppi, S., Ruaro, E. & Schneider, C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12, 471-480 (1996). Goruppi, S., Ruaro, E., Varnum, B. & Schneider, C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 17, 4442-
4453 (1997). Griendling, K.K. & Alexander, R.W. Endothelial control of the cardiovascular system: recent advances. Faseb J 10, 283-292 (1996). Hallenbeck, J.M. Cytokines, macrophages, and leukocytes in brain ischemia.
Neurology 49, S5-9 (1997). Ikeda, U., Takahashi, M. & Shimada, K. Monocyte-endothelial cell interaction in atherogenesis and thrombosis. Clin Cardiol lΛ , 11 -14 (1998). Kenny, B. A., Bushfield, M., Parry-Smith, D. J., Fogarty, S., and Treherne, J. M. (1998). The application of high-throughput screening to novel lead discovery.
Prog Drug Res 51, 245-69. Kockx, M.M. et al. The endothelium during cuff-induced neointima formation in the rabbit carotid artery. Arterioscler Thromb 13, 1874-1884 (1993).
Li, R. et al. Identification of Gas6 as a growth factor for human Schwann cells. J
Neurosci ΛQ, 2012-2019 (1996). Libby, P., Schwartz, D., Brogi, E., Tanaka, H. & Clinton, S.K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86, III47- 52 (1992).
Libby, P., Sukhova, G., Lee, R.T. & Liao, J.K. Molecular biology of atherosclerosis.
Int J Cardiol 62 Suppl 2, S23-29 (1997). Lusher, T.F., Tanner, F.C., Tschudi, M.R. & Noll, G. Endothelial dysfunction in coronary artery disease. Annu Rev Med 44, 395-418 (1993). Manfioletti, G., Brancolini, C, Avanzi, G. & Schneider, C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K- dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13, 4976-4985 (1993). McCloskey, P. et al. GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 272, 23285-23291 (1997).
McGill, S.N., Ahmed, N.A. & Christou, N.V. Endothelial cells: role in infection and inflammation. World J Surg 22, 171 -178 (1998). Moons, L. et al. Reduced transplant arteriosclerosis in plasminogen deficient mice. J
Clin Invest 102, 1788-1797 (1998). Murohara, T., Guo, J.P. & Lefer, A.M. Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J
Pharmacol Exp Ther 274, 1246-1253 (1995). Nagai, N., De Mol, M., Lijnen, H.R., Carmeliet, P. & Collen, D. Role of plasminogen system components in focal cerebral ischemic infarction. A gene targeting and gene transfer study in mice. Circulation (in press)(1999).
Nagata, K. et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem
271 , 30022-30027 (1996). Nakano, T. et al. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 323, 387-392 (1997a). Nakano, T. et al. Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6. J Biol Chem 272, 29411-29414 (1997b).
Pajkrt, D. & van Deventer, S.J. The cellular response in sepsis. Curr Top Microbiol
Immunol 216, 119-132 (1996). Ross, R. Atherosclerosis--an inflammatory disease. N Engl J Med 340, 115-126
(1999). Schaper, W. & Ito, W.D. Molecular mechanisms of coronary collateral vessel growth. Circ Res 79, 911-919 (1996). Schneider, C, King, R.M. & Philipson, L. Genes specifically expressed at growth arrest of mammalian cells. Ce//54, 787-793 (1988). Stitt, T.N. et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 80, 661-670
(1995). Vadas, M.A., Gamble, J.R., Rye, K. & Barter, P. Regulation of leucocyte-endothelial interactions of special relevance to atherogenesis. Clin Exp Pharmacol Physiol
24, A33-35 (1997)..
Tables
Table 1 : Coagulation and hematological parameters after endotoxin injection (20 mg/kg).
Data represent mean ± SD (5 mice) of plasma concentrations of coagulation factors (expresses in % of normal pool), platelets and leukocytes in mice within 12 h after injection of endotoxin (0-10 and 20 mg/kg).
Table 2: Serum cytokine concentration after endotoxin injection (20 mg/kg).
Data represent mean ± SD (7 mice) of cytokine serum concentrations in mice after injection of endotoxin (20 mg/kg).
Table 3: Endotoxin injection in the footpad All values in Gas6* mice are significantly different from those in Gasδ4^ mice (p<0.05)
Table 4: Activation of endothelial cells in vitro.
Data represent mean ± SD (9) of cytokine concentrations (ng/10 cells).
Table 5: Apoptosis of cultured endothelial cells
Data represent mean ± SD (n=9) of oligonucleosomes/10 cells. Table 6: Ischemic brain injury (stroke)
All values in Gas6"A mice are significantly different from those in
Gas6 ,+/+ mice (p<0.05)
Table 7: Matrigel Angiogenesis
p<0.05 versus Gas6 +/+
Claims
1. Non-human transgenic animal deficient in Gas6 function.
2. Non-human transgenic animal according to claim 1 in which said animal is Gas6"A.
3. Non-human transgenic animal according to claim 1 or 2 in which said animal is a mouse.
4. Use of an animal according to claim 1 -3 to study the role of Gas6 in endothelial activation.
5. Use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of a medicament for the treatment of endothelial dysfunction.
6. Use according to claim 5 in which endothelial dysfunction results in a cardiovascular disorder such as, but not limited to, stroke, arterial restenosis, myocardial infarction.
7. Use according to claim 5 in which endothelial dysfunction results in abnormal angiogenesis.
8. Use according to claim 5-7 in which the Gas6 receptor is AXL, MER and/or RSE.
9. Use according to claim 8 in which the inhibitor is a soluble form of the AXL, MER or RSE receptor.
10_Use according to claim 5-8 in which the inhibitor is a Gas6 neutralising antibody.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00935193A EP1185635A2 (en) | 1999-06-10 | 2000-06-08 | Non-human transgenic animals deficient in gas6 function and their use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99201859 | 1999-06-10 | ||
EP99201859 | 1999-06-10 | ||
PCT/EP2000/005318 WO2000076309A2 (en) | 1999-06-10 | 2000-06-08 | Non-human transgenic animals deficient in gas6 function and their use |
EP00935193A EP1185635A2 (en) | 1999-06-10 | 2000-06-08 | Non-human transgenic animals deficient in gas6 function and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1185635A2 true EP1185635A2 (en) | 2002-03-13 |
Family
ID=8240301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00935193A Withdrawn EP1185635A2 (en) | 1999-06-10 | 2000-06-08 | Non-human transgenic animals deficient in gas6 function and their use |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1185635A2 (en) |
AU (1) | AU5077100A (en) |
WO (1) | WO2000076309A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1199081A1 (en) * | 2000-10-20 | 2002-04-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Use of inhibition of a growth arrest-specific gene (gas6) function or of a gas6 receptor for preventing and treating a thromboembolic disease |
EP1272217A1 (en) * | 2000-04-13 | 2003-01-08 | Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) | Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease |
GB2374870A (en) * | 2001-01-26 | 2002-10-30 | Thromb X Nv | Use of genetically modified multicellular animals in the identification of drug target proteins |
DE10130657A1 (en) * | 2001-06-27 | 2003-01-16 | Axaron Bioscience Ag | New endothetially expressed protein and its use |
EP1382969A1 (en) * | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
AU2003286746A1 (en) | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
RU2490632C1 (en) * | 2012-05-17 | 2013-08-20 | Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения И Социального Развития Российской Федерации" | Method for stimulating endothelial dysfunction in vitro |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1179A (en) * | 1997-06-09 | 1999-01-06 | Shionogi & Co Ltd | Mouse having modified gas6 gene |
-
2000
- 2000-06-08 AU AU50771/00A patent/AU5077100A/en not_active Abandoned
- 2000-06-08 WO PCT/EP2000/005318 patent/WO2000076309A2/en not_active Application Discontinuation
- 2000-06-08 EP EP00935193A patent/EP1185635A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0076309A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU5077100A (en) | 2001-01-02 |
WO2000076309A2 (en) | 2000-12-21 |
WO2000076309A3 (en) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zi et al. | Involvement of cystatin C in immunity and apoptosis | |
Lillis et al. | LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies | |
Davalos et al. | Fibrinogen as a key regulator of inflammation in disease | |
Ploplis et al. | Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice | |
Gressner et al. | Roles of TGF-beta in hepatic fibrosis | |
Levi et al. | Systemic versus localized coagulation activation contributing to organ failure in critically ill patients | |
Carmeliet et al. | Gene manipulation and transfer of the plasminogen and coagulation system in mice | |
Wenzel et al. | Thrombomodulin–a new target for treating stroke at the crossroad of coagulation and inflammation | |
US7271152B2 (en) | Compounds and methods for the modulation of CD154 | |
EP1185635A2 (en) | Non-human transgenic animals deficient in gas6 function and their use | |
Schumacher et al. | ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer | |
Cho et al. | Aortic aneurysms: current pathogenesis and therapeutic targets | |
Yang et al. | Reduction in arthritis severity and modulation of immune function in tissue factor cytoplasmic domain mutant mice | |
JP2008539694A (en) | Compositions and methods for treating hemostatic disease by CLEC-2 signaling | |
CN108076629B (en) | GM-CSF negative regulator for treating, preventing or improving aortic disease | |
Wang et al. | Protective and detrimental effects of neuroectodermal cell–derived tissue factor in mouse models of stroke | |
WO2001078778A1 (en) | USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE | |
Matsuo et al. | A guide to murine fibrinolytic factor structure, function, assays, and genetic alterations | |
Liu et al. | The Role of Complement in the Pathogenesis of Artery Aneurysms | |
WO2002017711A2 (en) | Therapeutics and diagnostics based on a novel signal transduction system in platelets | |
Hoffman et al. | Localization of heparin cofactor II in injured human skin: a potential role in wound healing | |
Knoll Machado | Characterization of single point mutation in the gamma-carboxyglutamic acid domain of recombinant clotting Factor IX and its therapeutic potential | |
Bandaru | Filamin A in Cardiovascular Remodeling | |
Howell | The role of thrombin and protease activated receptor-1 in the pathogenesis of pulmonary fibrosis | |
Benson | The Role of the Duffy Antigen Receptor for Chemokines (DARC) in Ethnic Susceptibility to Cardiometabolic Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011224 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20030611 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060627 |